# Clinical Trials Data EGFR - Document 32

# Comparison of Sequencing and PNA Clamping of EGFR Gene in Patients With Non-Small Cell Type Lung Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01767974

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Locally advanced stage IIIB not suitable for curative therapy or stage IV (metastatic) disease or relapsed NSCLC\n\* ECOG Performance status 0\\~2.\n\* Written Informed Consent\n\* Female or male patients aged 18 years or over, eligible for treatment for NSCLC\n\nExclusion Criteria:\n\n\* Previous exposure to EGFR-TKI\n\* Concomitant use of other anti-cancer drugs with EGFR-TKI\n\* Patients without available Tumor DNA\n\* As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)\n\* Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study\n\* Pregnancy or breast-feeding women (women of child\u00acbearing potential). Women of childbearing potential must practice acceptable methods of birth control to prevent pregnancy.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
"stdAges": [  
"CHILD",  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Locally advanced stage IIIB or IV (metastatic) or Relapsed Non-Small Cell Lung Cancer",

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
No. The exclusion criteria specifically states "\* Previous exposure to EGFR-TKI\*". EGFR-TKIs are drugs specifically designed to target EGFR mutations. Therefore, a patient \*with\* an EGFR mutation would likely have already been treated with an EGFR-TKI and thus be ineligible for this particular trial.